{"success":true,"data":{"pressRelease":{"id":"78900","rtpr_id":"nGNX6nxV6w","ticker":"0013","exchange":"HKEX","all_tickers":["0013"],"title":"HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification","author":"Globe Newswire","published_at":"2026-07-02T08:30:00.142Z","article_body":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE NEWSWIRE)\n-- HUTCHMED (China) Limited (“HUTCHMED\n(https://www.globenewswire.com/Tracker?data=ThIGTF2Ckp00lDVdJyvkZsSSmliSf1TPYNQrSCzfgquMcof3DpFYd1lMn1ri9EWhTbNy8S6NKJZoX1L9tYzw5A==)”)\n(Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA)\nfor ORPATHYS(®) (savolitinib) has been granted conditional approval by the\nChina National Medical Products Administration (“NMPA”) for the treatment\nof locally advanced or metastatic gastric cancer or gastroesophageal junction\n(GC/GEJ) adenocarcinoma patients with MET amplification who have failed at\nleast two prior systemic treatments.\n\nGastric cancer remains one of the most common cancers and leading causes of\ncancer death in China. MET-driven gastric cancer has a very poor\nprognosis.(1) It is estimated that MET amplification accounts for\napproximately 4-6% of gastric cancer patients.(2)(,)(3) The annual incidence\nof MET amplification gastric cancer is estimated to be approximately 18,000\nin China.(4)\n\nThe approval is supported by data from the pivotal Phase II registration\nstudy of ORPATHYS(®) in gastric cancer or gastroesophageal junction\nadenocarcinoma patients with MET amplification in China (NCT04923932\n(https://www.globenewswire.com/Tracker?data=0z24_ROTnIul6iy7cRZ2sTPTVUOpHH4KmLL9MUPUAjgrvkaKw6q-6UC6IcQbC0MW7XT5FRTxnLpFWVMYjXJiatt9aUsks5SMCyUQMmvCEs1RVjZ15YPDnLhf7B0WzSNV)).\nThe results were recently published in Nature Medicine\n(https://www.globenewswire.com/Tracker?data=ZlYg2KP1eXUb_8CbawIes9Q1btM2iR7ATeuTvXQJGQRo0hXm13sMhbANUQoU5p8RBirp1zkpZqg-Va2HpIa4VEieltQEOMLoln4L6rgxO01WVK2UZbNFCNyyOc5tYmx4Erok3tQI_uAwB39MoOGTtA==)\nand highlighted at the American Society of Clinical Oncology (ASCO) Annual\nMeeting\n(https://www.globenewswire.com/Tracker?data=F2rnVEAyCFDQjpPfe5hiF7DLkt6VaQnhBgJR2Zwu9Q0rmPpzJjXUpbtM3ICUs2rj4wUcvb3ldlFIbBEQNosskQqCzE7ygUKh_Yzy_RbDE3sdrcuzA5E4go0hgg27pvmwmRQqXU-SQDj45WO0lHucyFdSus0Axm5N-3BfN4J0waMF4f8y3uujq0UgrmeS5K-1).\nThe study met its primary endpoint of objective response rate (“ORR”) per\nRECIST 1.1, as assessed by the Independent Review Committee (“IRC”). As of\nthe data cut-off of October 8, 2025, the IRC-assessed ORR was 32.3% (95%CI:\n21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary\nendpoints included the IRC-assessed disease control rate (DCR) of 63.1%,\nmedian time to response (TTR) of 1.4 months, median duration of response\n(DoR) of 9.7 (95%CI: 3.7, 18.5) months, and median progression-free survival\n(PFS) of 4.0 (95%CI: 2.6, 5.0) months, respectively.\n\n“This milestone approval marks a critical leap forward for biomarker-driven\nprecision medicine in gastrointestinal oncology,” said Professor Lin Shen of\nPeking University Cancer Hospital and leading Principal Investigator of the\nregistration study. “The clinical data from our pivotal study, recently\nrecognized and published by Nature Medicine, provided compelling evidence that\nidentifying MET amplification through timely molecular testing can directly\nguide patients to a highly effective, targeted oral option. ORPATHYS(®)’s\nentry into the MET-amplified gastric cancer clinical setting offers clinicians\na powerful, precise new tool to interrupt this aggressive oncogenic driver.”\n(5)\n\n“The approval of ORPATHYS(®) for MET-amplified advanced gastric cancer is\nan important achievement that underscores HUTCHMED’s enduring commitment to\nbringing in-house discovered innovations to patients,” said Mr Johnny Cheng,\nActing Chief Executive Officer and Chief Financial Officer of HUTCHMED.\n“This marks the third approved indication for ORPATHYS(®) in China and\nfurther validates our proprietary R&D platform’s ability to address deep\nunmet medical needs. Together with our partner AstraZeneca, we are proud to\nexpand the clinical application of this highly selective MET inhibitor and\nlook forward to accelerating its commercial availability to transform gastric\ncancer treatment landscapes in China.”\n\nMs Mary Guan, General Manager of AstraZeneca China Oncology Business, said:\n“Following its success in lung cancer, the approval of ORPATHYS(®) in\ngastric cancer marks another pivotal chapter in our joint development journey\nwith HUTCHMED. This regulatory milestone reinforces our shared vision of\npairing the right treatments with the right patients through precision\nmedicine. We look forward to maximizing the potential of this highly selective\nMET inhibitor and advancing its broader clinical lifecycle management to\naddress the evolving unmet needs of cancer patients in China and beyond.”\n\nAbout ORPATHYS(®)\n\nORPATHYS(®) (savolitinib) is an oral, potent, and highly selective MET\ntyrosine kinase inhibitor (TKI) being jointly developed by AstraZeneca and\nHUTCHMED and commercialized by AstraZeneca. MET is a tyrosine kinase receptor\nthat has an essential role in normal cell development.(6) ORPATHYS(®) blocks\natypical activation of the MET receptor tyrosine kinase pathway that occurs\nbecause of mutations (such as exon 14 skipping alterations or other point\nmutations), gene amplification or protein overexpression.\n\nORPATHYS(®) is approved in China and is marketed by our partner, AstraZeneca,\nrepresenting the first selective MET inhibitor approved in China. It has\nbeen included\n(https://www.globenewswire.com/Tracker?data=9QFFDr0fJUK_c0DEjmIeDwVMxxbtZXGZH5o9x2a3dsEFX5kcBai8q1QJzEpRn5-_gSi4sBa9p7stQgOtbOpLi2T-TVJd-eQoBO5mzIycx4IRUQxx2BkBAVsoknApNGtX) in\nthe National Reimbursement Drug List of China (NRDL) since March 2023.\n\nIt is currently under clinical development for multiple tumor types, including\nlung and gastric cancers as a single treatment and in combination with other\nmedicines.\n\nAbout HUTCHMED\n\nHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,\nbiopharmaceutical company. It is committed to the discovery and global\ndevelopment and commercialization of targeted therapies and immunotherapies\nfor the treatment of cancer and immunological diseases. Since inception it has\nfocused on bringing drug candidates from in-house discovery to patients around\nthe world, with its first three medicines marketed in China, the first of\nwhich is also approved around the world including in the US, Europe and Japan.\nFor more information, please visit: www.hutch-med.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=VulFj40irhW1Q_jEClztqBPNNntu_Hz5g8wbJbgdPAWD2Cb3aBWo3y-64eDufZvPi1lghZLb3lpE7zea-0-cMeYyICreWN2TFZiFbc6gxL8=).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the US Private Securities Litigation\nReform Act of 1995. These forward-looking statements reflect HUTCHMED’s\ncurrent expectations regarding future events, including its expectations\nregarding the therapeutic potential of ORPATHYS(®), the further clinical\ndevelopment for ORPATHYS(®), its expectations as to whether any studies on\nORPATHYS(®) would meet their primary or secondary endpoints, and its\nexpectations as to the timing of the completion and the release of results\nfrom such studies. Forward-looking statements involve risks and uncertainties.\nSuch risks and uncertainties include, among other things, assumptions\nregarding enrollment rates and the timing and availability of subjects meeting\na study’s inclusion and exclusion criteria; changes to clinical protocols or\nregulatory requirements; unexpected adverse events or safety issues; the\nability of ORPATHYS(®), including as a combination therapy, to meet the\nprimary or secondary endpoint of a study, to obtain regulatory approval in\nother jurisdictions and to gain commercial acceptance after obtaining\nregulatory approval; the potential market of ORPATHYS(®) for a targeted\nindication; and HUTCHMED and/or its partner’s ability to fund, implement and\ncomplete its further clinical development and commercialization plans for\nORPATHYS(®), and the timing of these events. Existing and prospective\ninvestors are cautioned not to place undue reliance on these forward-looking\nstatements, which speak only as of the date hereof. For further discussion of\nthese and other risks, see HUTCHMED’s filings with the US Securities and\nExchange Commission, The Stock Exchange of Hong Kong Limited and on AIM.\nHUTCHMED undertakes no obligation to update or revise the information\ncontained in this press release, whether as a result of new information,\nfuture events or circumstances or otherwise.\n\nMedical Information\n\nThis press release contains information about products that may not be\navailable in all countries, or may be available under different trademarks,\nfor different indications, in different dosages, or in different strengths.\nNothing contained herein should be considered a solicitation, promotion or\nadvertisement for any prescription drugs including the ones under development.\n\nCONTACTS\n\n Investor Enquiries                           +852 2121 8200 / ir@hutch-med.com                      \n                                                                                                     \n Media Enquiries                                                                                     \n FTI Consulting –                             +44 20 3727 1030 / HUTCHMED@fticonsulting.com          \n Ben Atwell / Tim Stamper                     +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)  \n Brunswick – Zhou Yi                          +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com  \n                                                                                                     \n Panmure Liberum                              Nominated Advisor and Joint Broker                     \n Atholl Tweedie / Emma Earl / Rupert Dearden  +44 20 7886 2500                                       \n                                                                                                     \n Cavendish                                    Joint Broker                                           \n Geoff Nash / Nigel Birks                     +44 20 7220 0500                                       \n                                                                                                     \n Deutsche Numis                               Joint Broker                                           \n Duncan Monteith / Ramin Naji                 +44 20 7545 8000                                       \n\n\n\n_____________________________\nREFERENCES\n\n (1)  Catenacci DV, Ang A, Liao WL, et al. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer . 2017;123(6):1061-1070. doi:10.1002/cncr.30437                                                                  \n (2)  Lee J, Kim ST, Kim K, et al. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discov . 2019;9(10):1388-1405. doi:10.1158/2159-8290.CD-19-044                                                                    \n (3)  Van Cutsem E, Karaszewska B, Kang YK, et al. A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors. Clin Cancer Res. 2019;25(8):2414-2423. doi:10.1158/1078-0432.CCR-18-1337  \n (4)  Global Cancer Observatory. China Fact Sheet. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf . Accessed April 7, 2025.                                                                                                                                  \n (5)  Peng Z, Liu T, Wang H. et al. Savolitinib in MET -amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med . Published online June 1, 2026. doi:10.1038/s41591-026-04459-7 (https://www.nature.com/articles/s41591-026-04459-7)                                  \n (6)  Uchikawa E, et al . Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074).                                                                                                                                                                                            \n                                                                                                                                                                                                                                                                                                      \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/085957ad-3bec-49ee-b13e-39961b83c7be)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6nxV6w","title":"HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification","author":"Globe Newswire","ticker":"0013","created":"2026-07-02T08:30:00.142Z","tickers":["0013"],"exchange":"HKEX","article_body":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE NEWSWIRE)\n-- HUTCHMED (China) Limited (“HUTCHMED\n(https://www.globenewswire.com/Tracker?data=ThIGTF2Ckp00lDVdJyvkZsSSmliSf1TPYNQrSCzfgquMcof3DpFYd1lMn1ri9EWhTbNy8S6NKJZoX1L9tYzw5A==)”)\n(Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA)\nfor ORPATHYS(®) (savolitinib) has been granted conditional approval by the\nChina National Medical Products Administration (“NMPA”) for the treatment\nof locally advanced or metastatic gastric cancer or gastroesophageal junction\n(GC/GEJ) adenocarcinoma patients with MET amplification who have failed at\nleast two prior systemic treatments.\n\nGastric cancer remains one of the most common cancers and leading causes of\ncancer death in China. MET-driven gastric cancer has a very poor\nprognosis.(1) It is estimated that MET amplification accounts for\napproximately 4-6% of gastric cancer patients.(2)(,)(3) The annual incidence\nof MET amplification gastric cancer is estimated to be approximately 18,000\nin China.(4)\n\nThe approval is supported by data from the pivotal Phase II registration\nstudy of ORPATHYS(®) in gastric cancer or gastroesophageal junction\nadenocarcinoma patients with MET amplification in China (NCT04923932\n(https://www.globenewswire.com/Tracker?data=0z24_ROTnIul6iy7cRZ2sTPTVUOpHH4KmLL9MUPUAjgrvkaKw6q-6UC6IcQbC0MW7XT5FRTxnLpFWVMYjXJiatt9aUsks5SMCyUQMmvCEs1RVjZ15YPDnLhf7B0WzSNV)).\nThe results were recently published in Nature Medicine\n(https://www.globenewswire.com/Tracker?data=ZlYg2KP1eXUb_8CbawIes9Q1btM2iR7ATeuTvXQJGQRo0hXm13sMhbANUQoU5p8RBirp1zkpZqg-Va2HpIa4VEieltQEOMLoln4L6rgxO01WVK2UZbNFCNyyOc5tYmx4Erok3tQI_uAwB39MoOGTtA==)\nand highlighted at the American Society of Clinical Oncology (ASCO) Annual\nMeeting\n(https://www.globenewswire.com/Tracker?data=F2rnVEAyCFDQjpPfe5hiF7DLkt6VaQnhBgJR2Zwu9Q0rmPpzJjXUpbtM3ICUs2rj4wUcvb3ldlFIbBEQNosskQqCzE7ygUKh_Yzy_RbDE3sdrcuzA5E4go0hgg27pvmwmRQqXU-SQDj45WO0lHucyFdSus0Axm5N-3BfN4J0waMF4f8y3uujq0UgrmeS5K-1).\nThe study met its primary endpoint of objective response rate (“ORR”) per\nRECIST 1.1, as assessed by the Independent Review Committee (“IRC”). As of\nthe data cut-off of October 8, 2025, the IRC-assessed ORR was 32.3% (95%CI:\n21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary\nendpoints included the IRC-assessed disease control rate (DCR) of 63.1%,\nmedian time to response (TTR) of 1.4 months, median duration of response\n(DoR) of 9.7 (95%CI: 3.7, 18.5) months, and median progression-free survival\n(PFS) of 4.0 (95%CI: 2.6, 5.0) months, respectively.\n\n“This milestone approval marks a critical leap forward for biomarker-driven\nprecision medicine in gastrointestinal oncology,” said Professor Lin Shen of\nPeking University Cancer Hospital and leading Principal Investigator of the\nregistration study. “The clinical data from our pivotal study, recently\nrecognized and published by Nature Medicine, provided compelling evidence that\nidentifying MET amplification through timely molecular testing can directly\nguide patients to a highly effective, targeted oral option. ORPATHYS(®)’s\nentry into the MET-amplified gastric cancer clinical setting offers clinicians\na powerful, precise new tool to interrupt this aggressive oncogenic driver.”\n(5)\n\n“The approval of ORPATHYS(®) for MET-amplified advanced gastric cancer is\nan important achievement that underscores HUTCHMED’s enduring commitment to\nbringing in-house discovered innovations to patients,” said Mr Johnny Cheng,\nActing Chief Executive Officer and Chief Financial Officer of HUTCHMED.\n“This marks the third approved indication for ORPATHYS(®) in China and\nfurther validates our proprietary R&D platform’s ability to address deep\nunmet medical needs. Together with our partner AstraZeneca, we are proud to\nexpand the clinical application of this highly selective MET inhibitor and\nlook forward to accelerating its commercial availability to transform gastric\ncancer treatment landscapes in China.”\n\nMs Mary Guan, General Manager of AstraZeneca China Oncology Business, said:\n“Following its success in lung cancer, the approval of ORPATHYS(®) in\ngastric cancer marks another pivotal chapter in our joint development journey\nwith HUTCHMED. This regulatory milestone reinforces our shared vision of\npairing the right treatments with the right patients through precision\nmedicine. We look forward to maximizing the potential of this highly selective\nMET inhibitor and advancing its broader clinical lifecycle management to\naddress the evolving unmet needs of cancer patients in China and beyond.”\n\nAbout ORPATHYS(®)\n\nORPATHYS(®) (savolitinib) is an oral, potent, and highly selective MET\ntyrosine kinase inhibitor (TKI) being jointly developed by AstraZeneca and\nHUTCHMED and commercialized by AstraZeneca. MET is a tyrosine kinase receptor\nthat has an essential role in normal cell development.(6) ORPATHYS(®) blocks\natypical activation of the MET receptor tyrosine kinase pathway that occurs\nbecause of mutations (such as exon 14 skipping alterations or other point\nmutations), gene amplification or protein overexpression.\n\nORPATHYS(®) is approved in China and is marketed by our partner, AstraZeneca,\nrepresenting the first selective MET inhibitor approved in China. It has\nbeen included\n(https://www.globenewswire.com/Tracker?data=9QFFDr0fJUK_c0DEjmIeDwVMxxbtZXGZH5o9x2a3dsEFX5kcBai8q1QJzEpRn5-_gSi4sBa9p7stQgOtbOpLi2T-TVJd-eQoBO5mzIycx4IRUQxx2BkBAVsoknApNGtX) in\nthe National Reimbursement Drug List of China (NRDL) since March 2023.\n\nIt is currently under clinical development for multiple tumor types, including\nlung and gastric cancers as a single treatment and in combination with other\nmedicines.\n\nAbout HUTCHMED\n\nHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,\nbiopharmaceutical company. It is committed to the discovery and global\ndevelopment and commercialization of targeted therapies and immunotherapies\nfor the treatment of cancer and immunological diseases. Since inception it has\nfocused on bringing drug candidates from in-house discovery to patients around\nthe world, with its first three medicines marketed in China, the first of\nwhich is also approved around the world including in the US, Europe and Japan.\nFor more information, please visit: www.hutch-med.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=VulFj40irhW1Q_jEClztqBPNNntu_Hz5g8wbJbgdPAWD2Cb3aBWo3y-64eDufZvPi1lghZLb3lpE7zea-0-cMeYyICreWN2TFZiFbc6gxL8=).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the US Private Securities Litigation\nReform Act of 1995. These forward-looking statements reflect HUTCHMED’s\ncurrent expectations regarding future events, including its expectations\nregarding the therapeutic potential of ORPATHYS(®), the further clinical\ndevelopment for ORPATHYS(®), its expectations as to whether any studies on\nORPATHYS(®) would meet their primary or secondary endpoints, and its\nexpectations as to the timing of the completion and the release of results\nfrom such studies. Forward-looking statements involve risks and uncertainties.\nSuch risks and uncertainties include, among other things, assumptions\nregarding enrollment rates and the timing and availability of subjects meeting\na study’s inclusion and exclusion criteria; changes to clinical protocols or\nregulatory requirements; unexpected adverse events or safety issues; the\nability of ORPATHYS(®), including as a combination therapy, to meet the\nprimary or secondary endpoint of a study, to obtain regulatory approval in\nother jurisdictions and to gain commercial acceptance after obtaining\nregulatory approval; the potential market of ORPATHYS(®) for a targeted\nindication; and HUTCHMED and/or its partner’s ability to fund, implement and\ncomplete its further clinical development and commercialization plans for\nORPATHYS(®), and the timing of these events. Existing and prospective\ninvestors are cautioned not to place undue reliance on these forward-looking\nstatements, which speak only as of the date hereof. For further discussion of\nthese and other risks, see HUTCHMED’s filings with the US Securities and\nExchange Commission, The Stock Exchange of Hong Kong Limited and on AIM.\nHUTCHMED undertakes no obligation to update or revise the information\ncontained in this press release, whether as a result of new information,\nfuture events or circumstances or otherwise.\n\nMedical Information\n\nThis press release contains information about products that may not be\navailable in all countries, or may be available under different trademarks,\nfor different indications, in different dosages, or in different strengths.\nNothing contained herein should be considered a solicitation, promotion or\nadvertisement for any prescription drugs including the ones under development.\n\nCONTACTS\n\n Investor Enquiries                           +852 2121 8200 / ir@hutch-med.com                      \n                                                                                                     \n Media Enquiries                                                                                     \n FTI Consulting –                             +44 20 3727 1030 / HUTCHMED@fticonsulting.com          \n Ben Atwell / Tim Stamper                     +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)  \n Brunswick – Zhou Yi                          +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com  \n                                                                                                     \n Panmure Liberum                              Nominated Advisor and Joint Broker                     \n Atholl Tweedie / Emma Earl / Rupert Dearden  +44 20 7886 2500                                       \n                                                                                                     \n Cavendish                                    Joint Broker                                           \n Geoff Nash / Nigel Birks                     +44 20 7220 0500                                       \n                                                                                                     \n Deutsche Numis                               Joint Broker                                           \n Duncan Monteith / Ramin Naji                 +44 20 7545 8000                                       \n\n\n\n_____________________________\nREFERENCES\n\n (1)  Catenacci DV, Ang A, Liao WL, et al. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer . 2017;123(6):1061-1070. doi:10.1002/cncr.30437                                                                  \n (2)  Lee J, Kim ST, Kim K, et al. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discov . 2019;9(10):1388-1405. doi:10.1158/2159-8290.CD-19-044                                                                    \n (3)  Van Cutsem E, Karaszewska B, Kang YK, et al. A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors. Clin Cancer Res. 2019;25(8):2414-2423. doi:10.1158/1078-0432.CCR-18-1337  \n (4)  Global Cancer Observatory. China Fact Sheet. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf . Accessed April 7, 2025.                                                                                                                                  \n (5)  Peng Z, Liu T, Wang H. et al. Savolitinib in MET -amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med . Published online June 1, 2026. doi:10.1038/s41591-026-04459-7 (https://www.nature.com/articles/s41591-026-04459-7)                                  \n (6)  Uchikawa E, et al . Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074).                                                                                                                                                                                            \n                                                                                                                                                                                                                                                                                                      \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/085957ad-3bec-49ee-b13e-39961b83c7be)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-02T08:30:00.185992392Z","server_sent_at_ms":1782981000185},"received_at":"2026-07-02T08:30:00.463Z","source_url":null},"analysis":{"id":"68144","press_release_id":"78900","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"fda_approval","narrative":"HUTCHMED received conditional approval from China's NMPA for ORPATHYS (savolitinib) to treat MET-amplified gastric cancer.\n\nThe approval is based on Phase 2 data showing a 32.3% objective response rate and targets an estimated 18,000 patients annually in China.\n\nThis marks the third indication for ORPATHYS in China, which is jointly developed with AstraZeneca and commercialized by AstraZeneca.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Third indication secured for ORPATHYS in China, targeting MET-amplified gastric cancer."},"keyFigures":{"drugName":"ORPATHYS (savolitinib)","phaseOfTrial":"Phase II","customDimensions":{"dcr":"63.1%","dor":"9.7 months","orr":"32.3%","pfs":"4.0 months","ttr":"1.4 months","patient_prevalence":"4-6%","annual_incidence_china":18000}},"quotedText":"This milestone approval marks a critical leap forward for biomarker-driven precision medicine in gastrointestinal oncology","namedEntities":{"people":[{"name":"Lin Shen","role":"Principal Investigator, Peking University Cancer Hospital"},{"name":"Johnny Cheng","role":"Acting Chief Executive Officer and Chief Financial Officer"},{"name":"Mary Guan","role":"General Manager, AstraZeneca China Oncology Business"}],"products":["ORPATHYS","savolitinib"],"companies":[{"name":"HUTCHMED","ticker":"0013"},{"name":"AstraZeneca","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Conditional approval from the NMPA for a third indication of ORPATHYS (savolitinib) in China. While conditional and targeting a niche patient subset (~4-6% prevalence), it validates the company's platform and expands the addressable market for its partnered asset."},"tickerRelevance":{"others":[],"primary":"0013"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":["product_launch"],"importanceComponents":{"geography":"China","eventGravity":"regulatory_approval","sectorWeight":"biotech"}},"event_type":"fda_approval","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":4,"narrative":"HUTCHMED received conditional approval from China's NMPA for ORPATHYS (savolitinib) to treat MET-amplified gastric cancer.\n\nThe approval is based on Phase 2 data showing a 32.3% objective response rate and targets an estimated 18,000 patients annually in China.\n\nThis marks the third indication for ORPATHYS in China, which is jointly developed with AstraZeneca and commercialized by AstraZeneca.","key_figures":{"drugName":"ORPATHYS (savolitinib)","phaseOfTrial":"Phase II","customDimensions":{"dcr":"63.1%","dor":"9.7 months","orr":"32.3%","pfs":"4.0 months","ttr":"1.4 months","patient_prevalence":"4-6%","annual_incidence_china":18000}},"named_entities":{"people":[{"name":"Lin Shen","role":"Principal Investigator, Peking University Cancer Hospital"},{"name":"Johnny Cheng","role":"Acting Chief Executive Officer and Chief Financial Officer"},{"name":"Mary Guan","role":"General Manager, AstraZeneca China Oncology Business"}],"products":["ORPATHYS","savolitinib"],"companies":[{"name":"HUTCHMED","ticker":"0013"},{"name":"AstraZeneca","relationship":"partner"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-04T16:59:00.145Z","global_importance":45,"audience_relevance":35,"importance_components":{"geography":"China","eventGravity":"regulatory_approval","sectorWeight":"biotech"}},"durationMs":1311086,"modelName":"george-droid-qwen-72b"}}